John McHutchison
Director/Board Member at ASSEMBLY BIOSCIENCES, INC.
Net worth: 282 239 $ as of 2023-05-30
Active connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Jason Okazaki | M | 48 | 4 years | |
| Per Lundin | M | 41 |
Evox Therapeutics Ltd.
 Evox Therapeutics Ltd. BiotechnologyHealth Technology Evox Therapeutics Ltd. develops and markets transformational therapeutics. The firm creates novel exosome-based biotherapeutics for the treatment of various severe diseases with limited options for patients and their families. The company was founded by Matthew Wood, Per Lundin, and Samir EL Andaloussi in 2016 and is headquartered in Oxford, the United Kingdom. | 8 years |
| Charles A. Gersbach | M | - |
Tune Therapeutics, Inc.
 Tune Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Tune Therapeutics, Inc. is a genetic medicine company based in Durham, NC. Tune Therapeutics is pioneering a new therapeutic modality with its versatile and powerful tempo epigenomic control platform. The platform has the potential to fine-tune any gene network and unlock the full power and potential of regenerative medicine. The company is driving through an inflection point in the history of genetic medicine by addressing thousands of common and complex diseases for which no curative treatment is available. Tune Therapeutics pioneers next-generation genetic therapies by exploring epigenomic control for discovering novel targets that are inaccessible to other approaches. The company was founded in 2020 by Fyodor Urnov, Akira Matsuno, Charles A. Gersbach. The CEO is Matt Kane. | - |
| William Ringo | M | 78 | 10 years | |
| Akira Matsuno | M | - |
Tune Therapeutics, Inc.
Tune Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Tune Therapeutics, Inc. is a genetic medicine company based in Durham, NC. Tune Therapeutics is pioneering a new therapeutic modality with its versatile and powerful tempo epigenomic control platform. The platform has the potential to fine-tune any gene network and unlock the full power and potential of regenerative medicine. The company is driving through an inflection point in the history of genetic medicine by addressing thousands of common and complex diseases for which no curative treatment is available. Tune Therapeutics pioneers next-generation genetic therapies by exploring epigenomic control for discovering novel targets that are inaccessible to other approaches. The company was founded in 2020 by Fyodor Urnov, Akira Matsuno, Charles A. Gersbach. The CEO is Matt Kane. | - |
| Andrew Dickinson | M | 54 | 8 years | |
| Daniel O'Day | M | 59 | 5 years | |
| Jeanette Bjorkquist | F | - | 5 years | |
| John O. Gunderson | M | - | 2 years | |
| Millie Ray | M | - |
Velia, Inc.
 Velia, Inc. Packaged SoftwareTechnology Services Velia, Inc. is a company based in San Francisco, CA that is focused on harnessing the therapeutic potential of a novel class of human peptides. These peptides regulate biological functions that are vital to human health. The company was founded by Alan Saghatelian, Jonathan Weissman, Eric Olson, and Richard Scheller. John G. McHutchison has been the CEO of the company since 2023. | - |
| Matt Kane | M | - |
Tune Therapeutics, Inc.
Tune Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Tune Therapeutics, Inc. is a genetic medicine company based in Durham, NC. Tune Therapeutics is pioneering a new therapeutic modality with its versatile and powerful tempo epigenomic control platform. The platform has the potential to fine-tune any gene network and unlock the full power and potential of regenerative medicine. The company is driving through an inflection point in the history of genetic medicine by addressing thousands of common and complex diseases for which no curative treatment is available. Tune Therapeutics pioneers next-generation genetic therapies by exploring epigenomic control for discovering novel targets that are inaccessible to other approaches. The company was founded in 2020 by Fyodor Urnov, Akira Matsuno, Charles A. Gersbach. The CEO is Matt Kane. | - |
| Nicole White | F | 44 | 11 years | |
| Lisa Johnson-Pratt | M | 60 | 3 years | |
| Susan Mahony | M | 59 | 7 years | |
| Kelly Kramer | F | 56 | 8 years | |
| Matthew Wood | M | - |
Evox Therapeutics Ltd.
Evox Therapeutics Ltd. BiotechnologyHealth Technology Evox Therapeutics Ltd. develops and markets transformational therapeutics. The firm creates novel exosome-based biotherapeutics for the treatment of various severe diseases with limited options for patients and their families. The company was founded by Matthew Wood, Per Lundin, and Samir EL Andaloussi in 2016 and is headquartered in Oxford, the United Kingdom. | 8 years |
| Jacqueline Barton | M | 71 | 6 years | |
| Gina Consylman | F | 52 | 4 years | |
| Paul Carter | M | 63 |
Evox Therapeutics Ltd.
Evox Therapeutics Ltd. BiotechnologyHealth Technology Evox Therapeutics Ltd. develops and markets transformational therapeutics. The firm creates novel exosome-based biotherapeutics for the treatment of various severe diseases with limited options for patients and their families. The company was founded by Matthew Wood, Per Lundin, and Samir EL Andaloussi in 2016 and is headquartered in Oxford, the United Kingdom. | 15 years |
| David Goeddel | M | 72 |
Velia, Inc.
Velia, Inc. Packaged SoftwareTechnology Services Velia, Inc. is a company based in San Francisco, CA that is focused on harnessing the therapeutic potential of a novel class of human peptides. These peptides regulate biological functions that are vital to human health. The company was founded by Alan Saghatelian, Jonathan Weissman, Eric Olson, and Richard Scheller. John G. McHutchison has been the CEO of the company since 2023. | - |
| Anthony Altig | M | 68 | 12 years | |
| Harish M. Manwani | M | 70 | 6 years | |
| Michael Houghton | M | 73 | 3 years | |
| Leon E. Chen | M | 49 |
Velia, Inc.
Velia, Inc. Packaged SoftwareTechnology Services Velia, Inc. is a company based in San Francisco, CA that is focused on harnessing the therapeutic potential of a novel class of human peptides. These peptides regulate biological functions that are vital to human health. The company was founded by Alan Saghatelian, Jonathan Weissman, Eric Olson, and Richard Scheller. John G. McHutchison has been the CEO of the company since 2023. | - |
| William Delaney | M | 52 | 4 years | |
| Anuj Gaggar | M | 46 | 1 years | |
| H. Hogan | M | 61 | 1 years | |
| Shannon Ryan | F | - | - | |
| Joydeep Ganguly | M | - | 5 years | |
| Millie Ray | M | - |
Velia, Inc.
Velia, Inc. Packaged SoftwareTechnology Services Velia, Inc. is a company based in San Francisco, CA that is focused on harnessing the therapeutic potential of a novel class of human peptides. These peptides regulate biological functions that are vital to human health. The company was founded by Alan Saghatelian, Jonathan Weissman, Eric Olson, and Richard Scheller. John G. McHutchison has been the CEO of the company since 2023. | - |
| Dan McHugh | M | - |
Tune Therapeutics, Inc.
Tune Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Tune Therapeutics, Inc. is a genetic medicine company based in Durham, NC. Tune Therapeutics is pioneering a new therapeutic modality with its versatile and powerful tempo epigenomic control platform. The platform has the potential to fine-tune any gene network and unlock the full power and potential of regenerative medicine. The company is driving through an inflection point in the history of genetic medicine by addressing thousands of common and complex diseases for which no curative treatment is available. Tune Therapeutics pioneers next-generation genetic therapies by exploring epigenomic control for discovering novel targets that are inaccessible to other approaches. The company was founded in 2020 by Fyodor Urnov, Akira Matsuno, Charles A. Gersbach. The CEO is Matt Kane. | - |
| Christine Bennett | M | 68 |
The Royal Australasian College of Physicians
| - |
| Kim Chan Koh | M | - |
The Royal Australasian College of Physicians
| - |
| Tomas Cihlar | M | 57 | 1 years | |
| Jyoti Mehra | F | 48 | 7 years | |
| Martin Andrews | M | 61 |
Evox Therapeutics Ltd.
Evox Therapeutics Ltd. BiotechnologyHealth Technology Evox Therapeutics Ltd. develops and markets transformational therapeutics. The firm creates novel exosome-based biotherapeutics for the treatment of various severe diseases with limited options for patients and their families. The company was founded by Matthew Wood, Per Lundin, and Samir EL Andaloussi in 2016 and is headquartered in Oxford, the United Kingdom. | 4 years |
| Johanna Mercier | F | 54 | 5 years | |
| Amrit Nagpal | M | - |
Evox Therapeutics Ltd.
Evox Therapeutics Ltd. BiotechnologyHealth Technology Evox Therapeutics Ltd. develops and markets transformational therapeutics. The firm creates novel exosome-based biotherapeutics for the treatment of various severe diseases with limited options for patients and their families. The company was founded by Matthew Wood, Per Lundin, and Samir EL Andaloussi in 2016 and is headquartered in Oxford, the United Kingdom. | - |
| Benjamin Scruggs | M | - |
Tune Therapeutics, Inc.
Tune Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Tune Therapeutics, Inc. is a genetic medicine company based in Durham, NC. Tune Therapeutics is pioneering a new therapeutic modality with its versatile and powerful tempo epigenomic control platform. The platform has the potential to fine-tune any gene network and unlock the full power and potential of regenerative medicine. The company is driving through an inflection point in the history of genetic medicine by addressing thousands of common and complex diseases for which no curative treatment is available. Tune Therapeutics pioneers next-generation genetic therapies by exploring epigenomic control for discovering novel targets that are inaccessible to other approaches. The company was founded in 2020 by Fyodor Urnov, Akira Matsuno, Charles A. Gersbach. The CEO is Matt Kane. | 2 years |
| Ali Behbahani | M | 47 |
Tune Therapeutics, Inc.
Tune Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Tune Therapeutics, Inc. is a genetic medicine company based in Durham, NC. Tune Therapeutics is pioneering a new therapeutic modality with its versatile and powerful tempo epigenomic control platform. The platform has the potential to fine-tune any gene network and unlock the full power and potential of regenerative medicine. The company is driving through an inflection point in the history of genetic medicine by addressing thousands of common and complex diseases for which no curative treatment is available. Tune Therapeutics pioneers next-generation genetic therapies by exploring epigenomic control for discovering novel targets that are inaccessible to other approaches. The company was founded in 2020 by Fyodor Urnov, Akira Matsuno, Charles A. Gersbach. The CEO is Matt Kane. | - |
| Adam Stoten | M | - |
Evox Therapeutics Ltd.
Evox Therapeutics Ltd. BiotechnologyHealth Technology Evox Therapeutics Ltd. develops and markets transformational therapeutics. The firm creates novel exosome-based biotherapeutics for the treatment of various severe diseases with limited options for patients and their families. The company was founded by Matthew Wood, Per Lundin, and Samir EL Andaloussi in 2016 and is headquartered in Oxford, the United Kingdom. | 8 years |
| Sarah Gordon-Wild | F | - |
Evox Therapeutics Ltd.
Evox Therapeutics Ltd. BiotechnologyHealth Technology Evox Therapeutics Ltd. develops and markets transformational therapeutics. The firm creates novel exosome-based biotherapeutics for the treatment of various severe diseases with limited options for patients and their families. The company was founded by Matthew Wood, Per Lundin, and Samir EL Andaloussi in 2016 and is headquartered in Oxford, the United Kingdom. | - |
| Eric Newell Olson | M | - |
Velia, Inc.
Velia, Inc. Packaged SoftwareTechnology Services Velia, Inc. is a company based in San Francisco, CA that is focused on harnessing the therapeutic potential of a novel class of human peptides. These peptides regulate biological functions that are vital to human health. The company was founded by Alan Saghatelian, Jonathan Weissman, Eric Olson, and Richard Scheller. John G. McHutchison has been the CEO of the company since 2023. | - |
| David Grimes | M | - |
The Royal Australasian College of Physicians
| 42 years |
| Jennifer A. Troia | F | - | 7 years | |
| Robert Cook | M | 65 | 12 years |
Connections Chart
Multi-company connection
Former connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Michael York | M | 59 | 2 years | |
| Derek Small | M | 48 | 6 years | |
| Uri Lopatin | M | 52 | 17 years | |
| Richard Heyman | M | 66 | 9 years | |
| John Milligan | M | 63 | 28 years | |
| Kenneth Song | M | 49 | 4 years | |
| Preston Klassen | M | 55 | 3 years | |
| Ronald M. Evans | M | 74 | 9 years | |
| Michael Samar | M | 51 | 5 years | |
| Thomas Russo | M | 52 | 9 years | |
| Elizabeth Lacy | F | 59 | 5 years | |
| Julia C. Owens | M | 51 | 2 years | |
| Michele Anderson | F | - | - | |
| Jeffrey Jonker | M | 51 | 2 years | |
| Andrew Cheng | M | 57 | 19 years | |
| Mark Auerbach | M | 85 | 10 years | |
| Antonin Rollet de Fougerolles | M | 59 |
Evox Therapeutics Ltd.
Evox Therapeutics Ltd. BiotechnologyHealth Technology Evox Therapeutics Ltd. develops and markets transformational therapeutics. The firm creates novel exosome-based biotherapeutics for the treatment of various severe diseases with limited options for patients and their families. The company was founded by Matthew Wood, Per Lundin, and Samir EL Andaloussi in 2016 and is headquartered in Oxford, the United Kingdom. | - |
| David Dornan | M | 46 | 5 years | |
| Monica Tellado | F | 51 | 9 years | |
| Gordon Earle Moore | M | 95 | 17 years | |
| Richard Colonno | M | 74 | 4 years | |
| Steve Kunszabo | M | - | - | |
| John Madigan | M | 86 | 12 years | |
| John Martin | M | 72 | 29 years | |
| Carol Gallagher | M | 59 | 3 years | |
| Richard DiMarchi | M | 71 | 9 years | |
| Norbert W. Bischofberger | M | 68 | 28 years | |
| Myron Holubiak | M | 77 | 12 years | |
| James M. Denny | M | 91 | 17 years | |
| Paul A. Berg | M | 97 | 13 years | |
| Andrew Guggenhime | M | 55 | 5 years | |
| Alan J. Lewis | M | 78 | 5 years | |
| Robert J. Adelman | M | 61 | 6 years | |
| Amir Nashat | M | 51 | 8 years | |
| Kevin B. Young | M | 66 | 10 years | |
| Kristina Burow | F | 50 | 7 years | |
| Catherine C. Lee | F | 50 | 2 years | |
| Patricia Millican | F | 51 | 7 years | |
| William Guyer | M | 56 | 6 years | |
| Arvinder Dhalla | M | - | 6 years | |
| Anthony D. Caracciolo | M | 68 | 13 years | |
| John Sundy | M | 62 | 6 years | |
| Kitty Yale | F | 52 | 17 years | |
| Craig S. Gibbs | M | 61 | 21 years | |
| David Johnson | M | 55 | 15 years | |
| Elizabeth Bhatt | F | 56 | 11 years | |
| Ramin Farzaneh-Far | M | 47 | 3 years | |
| Noreen Henig | M | 59 | 6 years | |
| Diane Wilfong | F | 62 | 7 years | |
| Jeffrey Hessekiel | M | 55 | 10 years | |
| Jeremy Bender | M | 52 | 2 years | |
| Alessandro Riva | M | 63 | 2 years | |
| Christopher Griffith | M | 47 | 5 years | |
| Marni Kottle | F | - | 8 years |
Statistics
| Country | Connections | % of total |
|---|---|---|
| United States | 90 | 90.00% |
| United Kingdom | 8 | 8.00% |
| Australia | 3 | 3.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- John McHutchison
- Personal Network